TIBSOVO’s Potential: Susan Pandya, MD, on FDA Priority Review for IDH1-Mutated MDS Acute Myelogenous Leukemia 1 Min Read8 In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and…
